Dr Reddy’s acquires Teva’s eight US products – Feedback

Dr Reddy’s Laboratories Ltd on Thursday said it has completed acquisition of eight Abbreviated New Drug Applications (ANDAs) in the US from Teva Pharmaceutical Industries Ltd and an affiliate of Allergan plc.

The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan’s generics business, the pharmaceuticals company said in a filing to BSE. The portfolio being acquired is a mix of six ANDAs pending approval, one approved ANDA and one ANDA with tentative approval and comprises complex generic products across diverse dosage forms.


About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *